Alumis Inc (ALMS NASDAQ) stock market data APIs
$22.9953
-0.33(-1.4%)
as of April 14, 2026
Try our APIs with
free plan!
Alumis Inc Financial Data Overview
Price chart is built with
Anychart
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Prev. Close
22.9953
Open
22.663
High
23.7103
Low
22.6306
52 wk Range
2.7601-30.6
Market Cap
2 865 M
Shares Outstanding
123 M
Revenue
24 050 K
EPS
-0.2526
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Alumis Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Alumis Inc data using free add-ons & libraries
Get Alumis Inc Fundamental Data
Alumis Inc Fundamental data includes:
- Net Revenue: 24 050 K
- EBITDA: -438 408 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-25
- EPS/Forecast: -0.9775
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Alumis Inc News
New
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results
Alumis Inc. (NASDAQ:ALMS) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 30, Raymond James reaffirmed its Strong Buy rating on Alumis Inc. (NASDAQ:ALMS) with a price targ...
Commit To Buy Alumis At $15, Earn 34.6% Annualized Using Options
Investors considering a purchase of Alumis Inc (Symbol: ALMS) stock, but cautious about paying the going market price of $23.76/share, might benefit from considering selling puts among the alternative...
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Alumis' (ALMS) recent phase 3 results for its psoriasis treatment envudeucitinib is "very positive" PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscrip...
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
